Phase I, Open-Label, 3-Way Crossover Trial in Healthy Volunteers to Determine the Drug-Drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2013
At a glance
- Drugs Rifampicin (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C; Tuberculosis
- Focus Pharmacokinetics
- Sponsors Janssen R&D Ireland
- 29 Jan 2009 Planned patient numbers amended from 18 to 21 as reported by ClinicalTrials.gov.
- 29 Jan 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 29 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.